etidronate has been researched along with Kahler Disease in 23 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-one patients with multiple myeloma were examined in close time relation with skeletal X-ray survey and bone scanning using technetium diphosphonate." | 7.66 | Skeletal scintigraphy with technetium diphosphonate in multiple myeloma--a comparison with skeletal x-ray. ( Lindström, E; Lindström, FD, 1980) |
| " We conclude that EHDP therapy used in this dosage schedule does not have a clinically significant impact in multiple myeloma." | 6.67 | Effect of daily etidronate on the osteolysis of multiple myeloma. ( Belch, AR; Bergsagel, DE; Johnston, D; O'Reilly, S; Pater, J; Sutton, D; Wilson, J; Wilson, K; Zee, B, 1991) |
| " Oral etidronate given daily showed no clinical benefit, whereas the use of oral clodronate daily did reduce the development of new osteolytic lesions but did not significantly affect bone pain or rates of pathologic fractures." | 6.18 | Bisphosphonates in multiple myeloma. ( Berenson, JR, 1997) |
| " One of the earliest agents to be investigated, etidronate, is effective in the management of malignant hypercalcemia and, when used orally and intermittently, results in reduced bone loss in osteoporosis." | 3.69 | Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer. ( Ashley, S; Hanson, J; Kanis, JA; McCloskey, E; Paterson, AH; Powles, TJ, 1995) |
| "Twenty-one patients with multiple myeloma were examined in close time relation with skeletal X-ray survey and bone scanning using technetium diphosphonate." | 3.66 | Skeletal scintigraphy with technetium diphosphonate in multiple myeloma--a comparison with skeletal x-ray. ( Lindström, E; Lindström, FD, 1980) |
| " We conclude that EHDP therapy used in this dosage schedule does not have a clinically significant impact in multiple myeloma." | 2.67 | Effect of daily etidronate on the osteolysis of multiple myeloma. ( Belch, AR; Bergsagel, DE; Johnston, D; O'Reilly, S; Pater, J; Sutton, D; Wilson, J; Wilson, K; Zee, B, 1991) |
| "Oral etidronate has been found to be ineffective in patients with multiple myeloma and prostate carcinoma bone metastases." | 2.41 | Oral bisphosphonates: A review of clinical use in patients with bone metastases. ( Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000) |
| "Myelomatosis is associated with considerable skeletal morbidity, particularly bone pain and fractures." | 2.41 | Bisphosphonates in multiple myeloma. ( Kanis, JA; McCloskey, EV, 2000) |
| "This is particularly true in multiple myeloma (MM), where bone involvement markedly influences the quality of life of patients." | 2.40 | The role of bisphosphonates for the treatment of bone disease in multiple myeloma. ( Musto, P, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (26.09) | 18.7374 |
| 1990's | 8 (34.78) | 18.2507 |
| 2000's | 6 (26.09) | 29.6817 |
| 2010's | 3 (13.04) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mhaskar, R | 2 |
| Kumar, A | 2 |
| Miladinovic, B | 2 |
| Djulbegovic, B | 2 |
| Lawson, MA | 1 |
| Coulton, L | 1 |
| Ebetino, FH | 2 |
| Vanderkerken, K | 1 |
| Croucher, PI | 1 |
| Berglund, J | 1 |
| Redzepovic, J | 1 |
| Wheatley, K | 1 |
| Clark, OA | 1 |
| Glasmacher, A | 1 |
| Wiesmann, A | 1 |
| Einsele, H | 1 |
| Kanz, L | 1 |
| Dohmen, BM | 1 |
| Roelofs, AJ | 1 |
| Hulley, PA | 1 |
| Meijer, A | 1 |
| Russell, RG | 2 |
| Shipman, CM | 1 |
| Kanis, JA | 3 |
| Paterson, AD | 1 |
| Raisz, LG | 1 |
| Lindström, E | 1 |
| Lindström, FD | 1 |
| Paterson, AH | 1 |
| Powles, TJ | 1 |
| McCloskey, E | 1 |
| Hanson, J | 1 |
| Ashley, S | 1 |
| Body, JJ | 1 |
| Coleman, RE | 1 |
| Piccart, M | 1 |
| Berenson, JR | 1 |
| Goa, KL | 1 |
| Balfour, JA | 1 |
| Lipton, A | 2 |
| Musto, P | 1 |
| Major, PP | 1 |
| Berenson, J | 1 |
| Hortobagyi, G | 1 |
| McCloskey, EV | 1 |
| Das, H | 1 |
| Wang, L | 1 |
| Kamath, A | 1 |
| Bukowski, JF | 1 |
| Rosen, C | 1 |
| Segal, H | 1 |
| Hartz, CE | 1 |
| Mroz, F | 1 |
| Carlton, E | 1 |
| Belch, AR | 1 |
| Bergsagel, DE | 1 |
| Wilson, K | 1 |
| O'Reilly, S | 1 |
| Wilson, J | 1 |
| Sutton, D | 1 |
| Pater, J | 1 |
| Johnston, D | 1 |
| Zee, B | 1 |
| Laroche, M | 1 |
| Arlet, P | 1 |
| Mazières, B | 1 |
| Arlet, J | 1 |
| Ryzen, E | 1 |
| Martodam, RR | 1 |
| Troxell, M | 1 |
| Benson, A | 1 |
| Paterson, A | 1 |
| Shepard, K | 1 |
| Hicks, R | 1 |
| Raper, RF | 1 |
| Ibels, LS | 1 |
9 reviews available for etidronate and Kahler Disease
| Article | Year |
|---|---|
Bisphosphonates in multiple myeloma: an updated network meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonat | 2017 |
Bisphosphonates in multiple myeloma: a network meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonat | 2012 |
Use of bisphosphonates in cancer patients.
Topics: Alendronate; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etid | 1996 |
Bisphosphonates in multiple myeloma.
Topics: Bone Diseases; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Multiple Mye | 1997 |
Risedronate.
Topics: Animals; Biological Availability; Bone Density; Bone Diseases, Metabolic; Bone Neoplasms; Bone Resor | 1998 |
Aredia: the once-monthly infusion for the treatment of bone metastases.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; | 1998 |
The role of bisphosphonates for the treatment of bone disease in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Bone Remodeling; Clinical Trials as Topic; Clodronic Acid; Diphospho | 1998 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasm | 2000 |
Bisphosphonates in multiple myeloma.
Topics: Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Multiple Myeloma; Pain; Pamid | 2000 |
2 trials available for etidronate and Kahler Disease
| Article | Year |
|---|---|
Bisphosphonates in multiple myeloma.
Topics: Bone Diseases; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Multiple Mye | 1997 |
Effect of daily etidronate on the osteolysis of multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Body Height; Cyclophosphamide; Dexa | 1991 |
13 other studies available for etidronate and Kahler Disease
| Article | Year |
|---|---|
Geranylgeranyl transferase type II inhibition prevents myeloma bone disease.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Count; Diphosphonates; Disease Model | 2008 |
Orthopaedics: Structural support.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Boronic Acids; Bortezomib; Diphosph | 2011 |
Complete remission after myeloablation with bone-seeking 186Re-HEDP and high-dose melphalan followed by autologous stem cell transplantation in a patient with chemorefractory multiple myeloma.
Topics: Bone and Bones; Disease-Free Survival; Etidronic Acid; Humans; Melphalan; Middle Aged; Multiple Myel | 2005 |
Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells.
Topics: Alkyl and Aryl Transferases; Apoptosis; Bone Density Conservation Agents; DNA Replication; Etidronic | 2006 |
The use of diphosphonates in myeloma.
Topics: Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Multiple Myeloma | 1983 |
New diphosphonates to block bone resorption.
Topics: Animals; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Double-Blind Method; Eti | 1980 |
Skeletal scintigraphy with technetium diphosphonate in multiple myeloma--a comparison with skeletal x-ray.
Topics: Bone Neoplasms; Diphosphonates; Etidronic Acid; Humans; Multiple Myeloma; Organotechnetium Compounds | 1980 |
Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; D | 1995 |
Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates.
Topics: Alendronate; Antigens; Cell Line, Transformed; Cytotoxicity, Immunologic; Diphosphonates; Etidronic | 2001 |
Primary hyperparathyroidism in an elderly patient with multiple myeloma.
Topics: Aged; Aged, 80 and over; Calcium; Cyclic AMP; Etidronic Acid; Humans; Hypercalcemia; Hyperparathyroi | 1992 |
[Efficacy of oral etidronic acid on pain and hypocalciuria in myeloma].
Topics: Administration, Oral; Aged; Calcium Metabolism Disorders; Etidronic Acid; Humans; Multiple Myeloma; | 1989 |
Intravenous etidronate in the management of malignant hypercalcemia.
Topics: Adult; Aged; Breast Neoplasms; Calcium; Carcinoma, Squamous Cell; Etidronic Acid; Female; Head and N | 1985 |
Osteosclerotic myeloma complicated by diffuse arteritis, vascular calcification and extensive cutaneous necrosis.
Topics: Adult; Aluminum Hydroxide; Arteritis; Bone Neoplasms; Calcinosis; Cyclophosphamide; Etidronic Acid; | 1985 |